MedeliX
Start asking

Naratriptan

ATC code N02CC02

Key facts
Active substance
Naratriptan
Drug class
Antimigraine
ATC code
N02CC02
Authorisation
authorised nationally; no central EU authorisation
Information as of
2026-10-29

Key facts

Naratriptan is a triptan (5-HT1B/1D agonist). Per the US prescribing information, it is used for the acute treatment of migraine with or without aura in adults.

What it is used for

  • Acute treatment of migraine with or without aura in adults
  • Use only when the diagnosis of migraine is clear; not for prevention of migraine attacks
  • Safety and effectiveness not established for cluster headache

Dosing

  • Recommended dose 1 mg or 2.5 mg
  • If migraine returns or response is partial, the dose may be repeated once after 4 hours; maximum 5 mg in 24 hours
  • Safety of treating an average of more than 4 attacks in 30 days not established
  • Mild to moderate renal or hepatic impairment: start with 1 mg, maximum 2.5 mg in 24 hours
  • Severe renal impairment (creatinine clearance below 15 mL/min) or severe hepatic impairment (Child-Pugh Grade C): contraindicated

Contraindications

  • Ischemic coronary artery disease or coronary artery vasospasm, including Prinzmetal's angina
  • Wolff-Parkinson-White syndrome or arrhythmias with accessory conduction pathways
  • History of stroke, TIA, or hemiplegic or basilar migraine
  • Peripheral vascular disease, ischemic bowel disease, uncontrolled hypertension
  • Severe renal or hepatic impairment; use within 24 hours of ergot drugs or other triptans

Important warnings

  • Myocardial ischemia, infarction and Prinzmetal's angina may occur, even without known CAD; cardiovascular evaluation before use in patients with multiple risk factors
  • Arrhythmias and chest, throat, neck or jaw pain or tightness
  • Cerebrovascular events and other vasospasm reactions
  • Medication overuse headache
  • Serotonin syndrome, increased blood pressure, hypersensitivity reactions

Side effects

  • Most common: paresthesias, dizziness, drowsiness, malaise/fatigue and throat/neck symptoms
  • Serious but rare: myocardial infarction, arrhythmias, stroke

Interactions

  • Ergot-containing drugs (e.g. dihydroergotamine, methysergide) and other 5-HT1 agonists: contraindicated within 24 hours
  • SSRIs, SNRIs, TCAs and MAO inhibitors: serotonin syndrome reported

Pregnancy and breastfeeding

  • No adequate data on developmental risk in pregnancy; developmental toxicity seen in animal studies

Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Patient information (US)

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

Germany

  • FormigranPharmasgp Gmbh · 1 register entry
  • NaradexDexcel Pharma Gmbh · 1 register entry
  • NaramigGlaxosmithkline Gmbh & Co. Kg · 1 register entry
  • Naratriptan1 A Pharma Gmbh, Ratiopharm Gmbh, Heumann Pharma Gmbh & Co. Generica Kg, Zentiva Pharma Gmbh, Stada Consumer Health Deutschland Gmbh, Neuraxpharm Arzneimittel Gmbh, Hormosan Pharma Gmbh, Aliud Pharma Gmbh, Hennig Arzneimittel Gmbh & Co. Kg, Hexal Ag, Stadapharm Gmbh, Betapharm Arzneimittel Gmbh, Juta Pharma Gmbh · 15 register entries

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

Brand names in 17 more European countries
Belgium
Naramig, Naratriptan Sandoz
Bulgaria
Нарворан Мигрена
Czechia
Naramig
Denmark
Naratriptan Teva, Naxtrin
Finland
Naramig, Naratriptan Orifarm
France
Naramig, Naratriptan Arrow, Naratriptan Biogaran, Naratriptan Eg, Naratriptan Sandoz, Naratriptan Teva, Naratriptan Viatris, Naratriptan Zentiva, Naratriptan Zydus
Ireland
Naratriptan, Naraverg
Lithuania
Naramig, Naratriptan Inteli
Luxembourg
Naramig
Malta
Naratriptan Renata Pharmaceuticals (Ireland)
Netherlands
Naramig, Naratriptan Cf, Naratriptan Hcl Teva, Naratriptan Sandoz, Naratriptan Viatris
Norway
Naratriptan Orifarm, Naxtrin
Portugal
Naramig, Naratriptano Renata
Romania
Nacralid, Naratriptan Stada Hemofarm
Slovenia
Naramig
Spain
Naramig
Sweden
Naramig, Naratriptan Orifarm, Naxtrin

EMA – Article 57 product data (EU/EEA), 2026-10-29

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. U.S. Food and Drug Administration. Naratriptan (Bionpharma Inc.) – Prescribing Information, 2026-06-30. DailyMed (NLM), 2026-10-29. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=93b7e6c2-e6a7-4f6b-9ecd-62d6bb0a6dda
  2. EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  3. Wikidata (CC0): ATC N02CC.

Editorial: Medelix editorial team · last updated 2026-10-29 · How these pages are made · Report an error

Source: U.S. Food and Drug Administration (FDA), prescribing information, via DailyMed (NLM); public domain. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.